Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Esophagitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    93 result(s) found for: Esophagitis. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2004-000492-33 Sponsor Protocol Number: BY1023/M3-904 Start Date*: 2004-09-06
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000493-32 Sponsor Protocol Number: BY1023/M3-906 Start Date*: 2004-08-17
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004806-25 Sponsor Protocol Number: BY1023/M3-339 Start Date*: 2005-04-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. ove...
    Medical condition: Gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001526-13 Sponsor Protocol Number: 23/2008/O/Sper Start Date*: 2008-06-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Efficacy of Gaviscon in the treatment of gastroesophageal reflux in preterm newborns
    Medical condition: gastroesophageal reflux in preterm newborns
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038262 Reflux esophagitis LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000711-10 Sponsor Protocol Number: BY1023/UK506 Start Date*: 2005-07-07
    Sponsor Name:ALTANA Pharma Ltd.
    Full Title: Determination of the performance characteristics of ReQuestTM in Practice in the stepped down management of GORD
    Medical condition: Gastro-oesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001302-16 Sponsor Protocol Number: IKP103/2008 Start Date*: 2008-06-30
    Sponsor Name:Medical Faculty, Otto-von-Guericke University
    Full Title: Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study)
    Medical condition: The presented study has to evaluate whether an optimized individual dosage of proton pump inhibitors, adjusted to CYP2C19 genotype, leads to a better pharmacokinetic effect (pH metric acid suppress...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038263 Reflux oesophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002934-12 Sponsor Protocol Number: 77/2007/U/Sper Start Date*: 2007-06-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: MANTEINANCE TREATMENT IN NERD PATIENT. A COMPARATIVE RANDOMIZED OPEN STUDY BETWEEN ALGINATE AND MAGALDRATE.
    Medical condition: Gastroesophageal reflux
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038263 Reflux oesophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003737-29 Sponsor Protocol Number: BUU-5/EEA Start Date*: Information not available in EudraCT
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophi...
    Medical condition: Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) NL (Completed) GR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003319-91 Sponsor Protocol Number: CX842A2201 Start Date*: 2021-02-08
    Sponsor Name:Cinclus Pharma AG
    Full Title: A randomized double-blind, double dummy, active comparator-controlled dose finding study in patients with reflux esophagitis Los Angeles grade C or D, and patients with at least partial symptom res...
    Medical condition: reflux esophagitis Los Angeles grade C or D and patients with grades A or B who partially responded to PPI patients with grades A or B who partially responded to PPI
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10038262 Reflux esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-002465-30 Sponsor Protocol Number: EE-01bude2014 Start Date*: Information not available in EudraCT
    Sponsor Name:Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica
    Full Title: Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis.
    Medical condition: Eosinophilic Esophagitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001484-12 Sponsor Protocol Number: BUL-1/EEA Start Date*: 2015-09-22
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathol...
    Medical condition: Active eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003226-23 Sponsor Protocol Number: APD334-206 Start Date*: 2021-02-02
    Sponsor Name:Arena Pharmaceuticals Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis
    Medical condition: Eosinophilic Esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001314-37 Sponsor Protocol Number: BUL-8/EEA Start Date*: 2021-04-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets fo...
    Medical condition: eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064212 Eosinophilic oesophagitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016692-29 Sponsor Protocol Number: BUU-2/EEA Start Date*: 2012-02-20
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspen...
    Medical condition: Active eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001786-12 Sponsor Protocol Number: CDX0159-08 Start Date*: 2023-03-31
    Sponsor Name:Celldex Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study)
    Medical condition: Eosinophilic esophagitis (EoE)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005842-39 Sponsor Protocol Number: 226361 Start Date*: 2013-12-20
    Sponsor Name:NU-sjukvården, Norra Älvsborgs Länssjukhus
    Full Title: Treatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnaires
    Medical condition: Eosinphilic Esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003516-39 Sponsor Protocol Number: BUL-3/EER Start Date*: 2021-04-28
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment...
    Medical condition: Maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001485-99 Sponsor Protocol Number: BUL-2/EER Start Date*: 2015-12-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mai...
    Medical condition: Maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) DK (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004335-24 Sponsor Protocol Number: CC-93538-EE-002 Start Date*: 2022-01-14
    Sponsor Name:Celgene International II Sàrl
    Full Title: A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
    Medical condition: EOSINOPHILIC ESOPHAGITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000213-20 Sponsor Protocol Number: D961WC00001 Start Date*: 2023-06-06
    Sponsor Name:Astrazeneca K.K.
    Full Title: An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients with ...
    Medical condition: Reflux esophagitis in Japanese paediatric patients Past gastric ulcer or duodenal ulcer in Japanese paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10038262 Reflux esophagitis LLT
    21.1 100000004865 10036904 Prophylaxis of NSAID gastric ulceration LLT
    20.0 100000004856 10013858 Duodenal ulcer, unspecified as acute or chronic, without mention of haemorrhage or perforation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 13:27:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA